Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.Nature|November 28, 2014
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Joseph Paul Eder, Gregg D Fine, et al.Journal for Immunotherapy of Cancer|June 8, 2023
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshopGuy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, et al.The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.The Lancet. Oncology|May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialKei Muro, Hyun Cheol Chung, Veena Shankaran, et al.British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.JAMA Oncology|September 23, 2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 StudyLeisha A Emens, Cristina Cruz, Joseph Paul Eder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2021
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)Evanthia T Roussos Torres, Christine Rafie, Chenguang Wang, et al.Pageof 4